Form4insider filings, from the source

SEC Form 4 · accession 0000921895-26-001688

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
BVF PARTNERS L P/IL
Director · Other
Inc/il Bvf
Director · Other
Mark N Lampert
Director · Other
BVF Partners OS Ltd.
Director · Other
BVF I GP LLC
Director · Other
BVF II GP LLC
Director · Other
BVF GP HOLDINGS LLC
Director · Other
Period of report
Jun 26, 2026
Accepted (ET)
Jun 26, 2026 · 6:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF1,F2Jun 26, 2026S837,914$106.50D1,960,881D
Common Stock, $0.0001 par valueF1,F3Jun 26, 2026S627,597$106.50D1,592,261D
Common Stock, $0.0001 par valueF1,F4Jun 26, 2026S113,289$106.50D240,123D
Common Stock, $0.0001 par valueF1,F5Jun 26, 2026S51,858$106.50D78,787ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Pre-Funded Warrants to Purchase Common StockF1,F2,F6$0.0001holding—————Common Stock, $0.0001 par value201,546201,546D
Pre-Funded Warrants to Purchase Common StockF1,F3,F6$0.0001holding—————Common Stock, $0.0001 par value156,742156,742D
Pre-Funded Warrants to Purchase Common StockF1,F2,F6$0.0001holding—————Common Stock, $0.0001 par value550,425550,425D
Pre-Funded Warrants to Purchase Common StockF1,F3,F6$0.0001holding—————Common Stock, $0.0001 par value375,856375,856D
Pre-Funded Warrants to Purchase Common StockF1,F4,F6$0.0001holding—————Common Stock, $0.0001 par value52,73352,733D
Pre-Funded Warrants to Purchase Common StockF1,F5,F6$0.0001holding—————Common Stock, $0.0001 par value27,79727,797I
Stock Option (Right to Buy)F7,F8$20.00holding————Aug 19, 2030Common Stock, $0.0001 par value40,12740,127I
Stock Option (Right to Buy)F7,F8$49.10holding————Jun 15, 2031Common Stock, $0.0001 par value20,06320,063I
Stock Option (Right to Buy)F7,F8$14.18holding————Jun 14, 2032Common Stock, $0.0001 par value12,00012,000I
Stock Option (Right to Buy)F7,F8$27.67holding————Jun 14, 2033Common Stock, $0.0001 par value12,00012,000I
Stock Option (Right to Buy)F7,F8$31.20holding————Jun 17, 2034Common Stock, $0.0001 par value16,00016,000I
Stock Option (Right to Buy)F7,F8$46.47holding————Jun 24, 2035Common Stock, $0.0001 par value16,00016,000I
Stock Option (Right to Buy)F7,F9$99.87holding————Jun 23, 2036Common Stock, $0.0001 par value6,0686,068I

Explanation of responses

Remarks

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.